Clinical Policy Title:	icatibant
Policy Number:	RxA.868
Drug(s) Applied:	Sajazir™, icatibant
Original Policy Date:	10/11/2024
Last Review Date:	03/25/2026
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Hereditary angioedema (HAE) (must meet all)**:**

1. Diagnosis of hereditary angioedema confirmed by one of the following (a or b):
   a. Low C1-INH antigenic or functional levels;
   b. Normal C1-INH levels, and at least one of the following (i or ii):
      i. Confirmed presence of mutation associated with the disease;
      ii. Recurring angioedema attacks that are refractory to high-dose antihistamines (i.e.,cetirizine 40 mg/day or equivalent for at least 1 month)
2. Prescribed for treatment of acute HAE attacks

Approval Duration
All Lines of Business (except Medicare): 12 months

II. Continued Therapy Approval

A. Hereditary angioedema (must meet all)**:**

1. Auto-approval based on lookback functionality within the past 120 days as a proxy for member responding positively to therapy

Approval Duration
All Lines of Business (except Medicare): 12 months

References

1. Sajazir Prescribing Information. Cambridge, CB3 0FA: Cycle Pharmaceuticals Ltd; February 2024. Available at: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1756aca0-21a1-4898-8d6c-9666738db45c&type=display#section-1. Accessed October 11, 2024.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	10/11/2024	12/05/2024
Policy was reviewed 1. Continuation language updated.	03/25/2026	03/26/2026

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

© 2024 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.

© 2024 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.